Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Enleofen

- PMLiVE

IFPMA launches AMR Action Fund to tackle antimicrobial resistance

Pharma and health organisations unite to address public health threat

- PMLiVE

FDA says no to Lilly, Boehringer’s Jardiance in type 1 diabetes

Formally rejects extended use of SGLT2 inhibitor

- PMLiVE

FDA clears wider use for Boehringer’s Ofev in lung disease

Drug was first approved in 2014 for pulmonary fibrosis

- PMLiVE

Zydus Cadila scores first ever NASH approval, in India

Drug has already been approved for diabetes related conditions

- PMLiVE

Boehringer links up with Trutino for cancer R&D

Collaboration agreement will focus on cytokine treatments

- PMLiVE

FDA delays decision on Intercept’s NASH drug by three months

Action date pushed back to 26 June

- PMLiVE

Keeping up the fight against HIV and using the lessons to tackle other threats

Danny Buckland interviews Gilead’s Mike Elliott

- PMLiVE

Boehringer bolsters NASH pipeline with Enleofen link-up

Agrees to pay up to €1bn for each new marketed product

- PMLiVE

Northsea Therapeutics raises $40m to develop fish oil NASH drug

Looking for mid-stage trial success in field littered with failures

- PMLiVE

Boehringer Ingelheim to manufacture first biologic in China under new reforms

German pharma will manufacture BeiGene's PD-1 inhibitor

- PMLiVE

Gilead’s NASH hopes crushed as candidates fail again

Monotherapy and combination regimens produced disappointing results

- PMLiVE

CymaBay Therapeutics plummets after abandoning NASH drug

Failure of mid-stage liver disease candidate caused shares to slip over 75%

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links